Ling Yunyu

Dr. Ling Yunyu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Cytokine
Verified
Journal Article
Closed access
LGLihong Gan
Lihong Gan
ZLZheng Li
Zheng Li
LYLing Yunyu
Ling Yunyu
LLLing Lei
Ling Lei
YHYaqin Huang
Yaqin Huang
NFNian Fang
Nian Fang


28 February 2025 in Machines
Verified
Journal Article
Open access
PDF file
LYLing Yunyu
Ling Yunyu
BLBenyou Liu
Benyou Liu
HZHongxin Zhang
Hongxin Zhang
LBLan Bo
Lan Bo
MLMingjie Liu
Mingjie Liu
Inspired by the wing-flapping action of birds, this study considers the inherent dynamics among vehicle mechanisms to optimize the vehicle’s geometric parameters. The goal is for the vehicle to imitate the wing-flapping action of birds while minimizing energy consumption and the peak torque during flapping. To accomplish this, a dynamics model and an energy consumption model are established for the vehicle drive mechanism, followed by a multi-objective optimization under the boundary conditions of each parameter. Because of the complexity of the model, a mathematical tool that combines the genetic algorithm with the augmented Lagrange multiplier method is adopted in the optimization process. Simulation results show that the optimized energy consumption and peak moments are reduced. The proposed method provides a theoretical basis for designing a reliable flap-winged vehicle with reasonable parameter choices.

1 January 2023 in Neoplasma
Verified
Journal Article
Open access
JYJin-Hua Yan
Jin-Hua Yan
LYLing Yunyu
Ling Yunyu
YTYing Tan
Ying Tan
Yue WangYue Wang
Yue Wang
LINC00504 promotes the progression of acute myeloid leukemia by targeting MDM2

31 March 2023
Verified
Other
Open access
YZYi-Zi Zheng
Yi-Zi Zheng
MXMeng-Zhu Xue
Meng-Zhu Xue
HSHong-Jie Shen
Hong-Jie Shen
Xiaoguang LiXiaoguang Li
Xiaoguang Li
DMDing Ma
Ding Ma
ZSZhi-Ming Shao
Zhi-Ming Shao
Alternative splicing (AS) and its regulation play critical roles in cancer, yet the dysregulation of AS and its molecular bases in breast cancer development have not yet been elucidated. Using an in vivo CRISPR screen targeting RNA-binding proteins, we identified PHD finger protein 5A (PHF5A) as a key splicing factor involved in tumor progression. PHF5A expression was frequently upregulated in breast cancer and correlated with poor survival, and knockdown of PHF5A significantly suppressed cell proliferation, migration, and tumor formation. PHF5A was required for SF3b spliceosome stability and linked the complex to histones, and the PHF5A–SF3b complex modulated AS changes in apoptotic signaling. In addition, expression of a short truncated FAS-activated serine/threonine kinase (FASTK) protein was increased after PHF5A ablation and facilitated Fas-mediated apoptosis. This PHF5A-modulated FASTK–AS axis was widely present in breast cancer specimens, particularly those of the triple-negative subtype. Taken together, our findings reveal that PHF5A serves as an epigenetic suppressor of apoptosis and thus provides a mechanistic basis for breast cancer progression and may be a valuable therapeutic target.Significance: This study provides an epigenetic mechanistic basis for the aggressive biology of breast cancer and identifies a translatable therapeutic target. Cancer Res; 78(12); 3190–206. ©2018 AACR.

16 September 2023 in World Journal of Clinical Cases
Verified
Journal Article
Open access
LZLi Zheng
Li Zheng
LGLi-Hong Gan
Li-Hong Gan
LYLing Yunyu
Ling Yunyu
BLBin Li
Bin Li
YHYa-Qin Huang
Ya-Qin Huang
NFNian Fang
Nian Fang
The incidence and mortality rates of gastric cancer in China are the second-highest in the world, and most patients with gastric cancer lose their chance of surgery by the time of their diagnosis. To explore the predictive potential of serum basic fibroblast growth factor and interleukin-1β levels for the effect of first-line chemotherapy in patients with advanced gastric cancer. From the gastric cancer patients admitted to our hospital from May 2019 to April 2023, 84 patients were selected and randomly and equally assigned to the experimental or control group. The FLOT group received the FLOT chemotherapy regimen (composed of oxaliplatin + calcium folinate + fluorouracil + paclitaxel), while the SOX group received the SOX chemotherapy regimen (composed of oxaliplatin + tiga capsules). The clinical efficacy, tumor marker levels, adverse reactions, and survival rates of the two groups were compared 7 days after the end of the relevant treatments. The target effective rate of the FLOT group was 54.76%, which was much higher than that of the SOX group (33.33%; P < 0.05). After treatment, both the groups demonstrated lower levels of cancer antigen (CEA), carbohydrate antigen 199 (CA199), and peptide tissue antigen (TPS). For several patients before treatment (P < 0.05). Third and fourth grades. In terms of adverse reactions, the level of white blood cells in both the groups was lower. Moreover, the incidence of hand-foot skin reactions in these two study groups was lower (P < 0.05), while those of peripheral neuritis, vomiting, diarrhea, and abnormal liver function were significant (P < 0.05). No statistically significant difference was noted between the two groups (P < 0.05). The 1-year survival rate was higher in the FLOT group (P < 0.05). The FLOT regimen was effective in reducing the serum CEA, CA199, and TPS levels as well as in improving the 1-year survival rate of patients with good tolerability, making it worthy of clinical promotion and application.